抗菌薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Antibacterial Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Antibacterial: overview
Introduction
Mechanism of action
General principles for the use of antibiotics
Clinical uses
Epidemiology

PART 06: Pipeline analysis
Zerbaxa
Surotomycin
MK-3415A
Amikacin Inhale
CARBAVANCE
Eravacycline
Plazomicin
Delafloxacin
Solithromycin
VivaGel
Arikayce
Cadazolid
Ozenoxacin

PART 07: Antimicrobial resistance
Sources of spread of resistant organisms
Initiatives to improve antibiotic innovation

PART 08: Legislation relating to antibiotic use in the US

PART 09: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 10: Market segmentation by chemical class
Beta-lactam
Macrolides
Aminoglycosides
Phenicols
Quinolones
Folate antagonists
Tetracyclines
Others

PART 11: Market segmentation by drug origin
Natural
Semisynthetic
Synthetic

PART 12: Market segmentation by mechanism of action
Bacteriostatic
Bactericidal

PART 13: Market segmentation by spectrum of activity
Broad spectrum antibiotics
Narrow spectrum antibiotics

PART 14: Geographical segmentation
Global antibacterial drugs market by geographical segmentation 2014-2019
Antibacterial drugs market in APAC
Antibacterial drugs market in EMEA
Antibacterial drugs market in Americas

PART 15: Market drivers
Special regulatory designations
Increase in prevalence of infections
Increase in awareness
Increase in aging population

PART 16: Impact of drivers

PART 17: Market challenges
Development of drug resistant strains
Patent expiries and generic penetration
Decreased investments in research activities

PART 18: Impact of drivers and challenges

PART 19: Market trends
Strategic alliances and M&A
Patient assistance programs
Increased funding on antibiotic research

PART 20: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 21: Key vendor analysis
Allergan
GSK
Merck
Pfizer
Sandoz
Teva Pharmaceuticals

PART 22: Appendix
List of abbreviation

PART 23: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Mechanism of action of antibacterial drugs
Exhibit 03: General principles involved in the use of antibiotics
Exhibit 04: Estimated number of cases for nosocomial infections in US, 2011
Exhibit 05: Number of cases for Escherichia coli bacteremia in UK, 2012-2014
Exhibit 06: Global antibacterial drugs market: Pipeline portfolio
Exhibit 07: Causes of antimicrobial resistance
Exhibit 08: Sources of spread of resistant organisms
Exhibit 09: Estimated deaths per year caused by AMR in 2050
Exhibit 10: Initiatives improving antibiotic innovation
Exhibit 11: Legislation relating to antibiotic use in US
Exhibit 12: Global antibacterial drugs market 2014-2019 ($ billions)
Exhibit 13: Five forces analysis
Exhibit 14: Global antibacterial drugs market segmentation by chemical class
Exhibit 15: Cephalosporin segmentation by generation of drugs
Exhibit 16: Global antibacterial drugs market revenue segmentation by chemical class
Exhibit 17: Global antibacterial drugs market segmentation by drug origin
Exhibit 18: Global antibacterial drugs market segment by geography 2014
Exhibit 19: Antibacterial drugs market revenue by geography 2014-2019 ($ billions)
Exhibit 20: Antibacterial drugs market in APAC 2014-2019 ($ billions)
Exhibit 21: Antibacterial drugs market in EMEA 2014-2019 ($ billions)
Exhibit 22: Antibacterial drugs market in Americas 2014-2019 ($ billions)
Exhibit 23: Percentage share of antibacterial drugs market in Americas
Exhibit 24: Impact of drivers
Exhibit 25: Antibiotic-resistant strains according to the period of development of resistance
Exhibit 26: Antibacterial drug approvals by FDA and EMA
Exhibit 27: Impact of drivers and challenges
Exhibit 28: Allergan: YoY growth and revenue generated from net product sales of anti-infective 2011-2013 ($ millions)
Exhibit 29: Allergan: Key takeaways
Exhibit 30: GlaxoSmithKline: YoY growth and revenue generated from sales of Augmentin 2011-2014 ($ millions)
Exhibit 31: GlaxoSmithKline: Revenue generated from sales of Augmentin by region 2011-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: YoY growth and revenue generated from sales of other antibacterials 2011-2013 ($ millions)
Exhibit 33: GlaxoSmithKline: Key takeaways
Exhibit 34: Merck: YoY growth and revenue generated from sales of Primaxin 2012-2014 ($ millions)
Exhibit 35: Merck: YoY growth and revenue generated from sales of Invanz 2012-2014 ($ millions)
Exhibit 36: Merck: Key takeaways
Exhibit 37: Pfizer: YoY growth and revenue generated from sales of Zyvox 2012-2014 ($ millions)
Exhibit 38: Pfizer: YoY growth and revenue generated from sales of Zithromax/Zmax 2012-2014 ($ millions)
Exhibit 39: Pfizer: YoY growth and revenue generated from sales of Unasyn 2012-2014 ($ millions)
Exhibit 40: Pfizer: YoY growth and revenue generated from sales of Zosyn/Tazocin 2012-2014 ($ millions)
Exhibit 41: Pfizer: YoY growth and revenue generated from sales of Sulperazon 2012-2014 ($ millions)
Exhibit 42: Pfizer: YoY growth and revenue generated from sales of Tygacil 2012-2014 ($ millions)
Exhibit 43: Pfizer: Key takeaways
Exhibit 44: Sandoz: Key takeaways
Exhibit 45: Teva Pharmaceuticals: Key takeaways
Exhibit 46: Allergan: Business segmentation by product revenue 2014
Exhibit 47: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 48: Allergan: Geographical segmentation by revenue 2014
Exhibit 49: GSK: Business segmentation by revenue 2014
Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 51: GSK: Geographical segmentation by revenue 2014
Exhibit 52: Merck: Business segmentation by revenue 2014
Exhibit 53: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 54: Merck: Geographical segmentation by revenue 2014
Exhibit 55: Pfizer: Business segmentation by revenue 2014
Exhibit 56: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 57: Pfizer: Geographical segmentation by revenue 2014
Exhibit 58: Sandoz: Business segmentation by revenue 2014
Exhibit 59: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 60: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
Exhibit 61: Teva Pharmaceuticals: Geographical segmentation by revenue 2014


【レポート販売概要】

■ タイトル:抗菌薬の世界市場2015-2019
■ 英文:Global Antibacterial Drugs Market 2015-2019
■ 発行日:2015年11月11日
■ 調査会社:Technavio
■ 商品コード:IRTNTR7883
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。